Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027

Mark T. Reding; Ingrid Pabinger; Shadan Lalezari; Elena Santagostino; Maria Elisa Mancuso

doi:10.1111/hae.13982

Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027

Mark T. Reding, Ingrid Pabinger, Shadan Lalezari, Elena Santagostino, Maria Elisa Mancuso

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e201-e204
Journal	Haemophilia
Volume	26
Issue number	4
DOIs	https://doi.org/10.1111/hae.13982
State	Published - Jul 1 2020

Bibliographical note

Funding Information:
Dr Inga Bayh of Bayer AG, Wuppertal, Germany, was responsible for the statistical analysis of this study. This study was supported by Bayer. Medical writing assistance was provided by Fishawack Communications Ltd., which was fully funded by Bayer.

Keywords

BAY 94-9027
PROTECT VIII trial
bleeding
damoctocog alfa pegol
haemophilia A
target joint

Publisher link

10.1111/hae.13982

Find It

Find It at U of M Libraries

Cite this

@article{8092d8e60be64c2a9e1d8a1c6d18ab66,

title = "Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027",

keywords = "BAY 94-9027, PROTECT VIII trial, bleeding, damoctocog alfa pegol, haemophilia A, target joint",

author = "Reding, {Mark T.} and Ingrid Pabinger and Shadan Lalezari and Elena Santagostino and Mancuso, {Maria Elisa}",

note = "Funding Information: Dr Inga Bayh of Bayer AG, Wuppertal, Germany, was responsible for the statistical analysis of this study. This study was supported by Bayer. Medical writing assistance was provided by Fishawack Communications Ltd., which was fully funded by Bayer. ",

year = "2020",

month = jul,

day = "1",

doi = "10.1111/hae.13982",

language = "English (US)",

volume = "26",

pages = "e201--e204",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027

AU - Reding, Mark T.

AU - Pabinger, Ingrid

AU - Lalezari, Shadan

AU - Santagostino, Elena

AU - Mancuso, Maria Elisa

N1 - Funding Information: Dr Inga Bayh of Bayer AG, Wuppertal, Germany, was responsible for the statistical analysis of this study. This study was supported by Bayer. Medical writing assistance was provided by Fishawack Communications Ltd., which was fully funded by Bayer.

PY - 2020/7/1

Y1 - 2020/7/1

KW - BAY 94-9027

KW - PROTECT VIII trial

KW - bleeding

KW - damoctocog alfa pegol

KW - haemophilia A

KW - target joint

UR - http://www.scopus.com/inward/record.url?scp=85087165471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087165471&partnerID=8YFLogxK

U2 - 10.1111/hae.13982

DO - 10.1111/hae.13982

M3 - Letter

C2 - 32578323

AN - SCOPUS:85087165471

SN - 1351-8216

VL - 26

SP - e201-e204

JO - Haemophilia

JF - Haemophilia

IS - 4

ER -

Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Cite this